Conversely, although direct evidence in NSCLC is limited, MAPK pathway reactivation - including BRAF and MEK/ERK signaling - has been observed in ALK inhibitor resistance models, potentially reducing the efficacy of agents such as Ceritinib and Alectinib[49,50]. Here, ALK is linked to non-small cell lung carcinoma.